These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 3115602)

  • 21. [Leptilan. Dissolution, bioavailability and first therapeutic results in children with different epilepsy forms].
    Windorfer A; Hermannsdörfer-Tröltzsch G; Kienholz M; Maier-Lenz H; Löhr W; Stoll KD
    Fortschr Med; 1981 Oct; 99(37):1516-22. PubMed ID: 6795098
    [No Abstract]   [Full Text] [Related]  

  • 22. [Problems of therapeutic service in valproate therapy].
    Köhler E; Quednow B; Walther H
    Z Arztl Fortbild (Jena); 1980 Aug; 74(15):694-7. PubMed ID: 6777996
    [No Abstract]   [Full Text] [Related]  

  • 23. [Sodium valproate (Na VPa) monotherapy in childhood epilepsy ].
    Dulac O; Steru D; Rey E; Arthuis M
    Arch Fr Pediatr; 1982; 39(6):347-52. PubMed ID: 6812534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Valproic acid in childhood epilepsy: anticonvulsive efficacy in relation to its plasma levels.
    Klotz U; Schweizer C
    Int J Clin Pharmacol Ther Toxicol; 1980 Oct; 18(10):461-5. PubMed ID: 6782028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of total and free anticonvulsant serum levels in clinical practice.
    Beran RG; Lewis JH; Nolte JL; Westwood AP
    Clin Exp Neurol; 1985; 21():69-77. PubMed ID: 3939613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valproate-associated coagulopathies are frequent and variable in children.
    Attilakos A; Katsarou E; Voudris K; Garoufi A
    Epilepsia; 2007 Jan; 48(1):205-6. PubMed ID: 17241231
    [No Abstract]   [Full Text] [Related]  

  • 27. Single and chronic dose pharmacokinetic studies of sodium valproate in epileptic patients.
    Mihaly GW; Vajda FJ; Miles JL; Louis WJ
    Eur J Clin Pharmacol; 1979 Aug; 16(1):23-9. PubMed ID: 387418
    [No Abstract]   [Full Text] [Related]  

  • 28. [Sudden death in epileptics treated with valproic acid].
    Rodat O; Nicolas G; Anger JP; Develay-Legueut MA; Michaux P
    Acta Med Leg Soc (Liege); 1985; 35(1):123-34. PubMed ID: 2979871
    [No Abstract]   [Full Text] [Related]  

  • 29. Valproate-induced proximal renal tubular dysfunction: clinically relevant in the severely disabled epileptic population.
    Jaffe SL; Sanford M
    Epilepsia; 2005 Apr; 46(4):599-600. PubMed ID: 15816962
    [No Abstract]   [Full Text] [Related]  

  • 30. Therapeutic drug monitoring of antiepileptic drugs.
    Shakya G; Malla S; Shakya KN; Shrestha R
    JNMA J Nepal Med Assoc; 2008; 47(171):94-7. PubMed ID: 19079370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Combination therapy with carbamazepine and valproic acid in problem cases at an outpatient epilepsy clinic].
    Fröscher W; Stoll KD; Hoffmann F
    Arzneimittelforschung; 1984; 34(8):910-4. PubMed ID: 6437416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged use of phenytoin, carbamazepine or valproate monotherapy on plasma levels of folate and B(12): a comparison between epileptic patients with or without cardiovascular disorders.
    Otoom S; Bakhiet M; Khan A; Sequeira R
    Neuro Endocrinol Lett; 2006; 27(1-2):85-8. PubMed ID: 16648782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Valproate and palmitate binding to serum albumin in valproate-treated patients. Relation to obesity.
    Vorum H; Gram L; Honoré B
    Epilepsy Res; 1993 Sep; 16(1):55-64. PubMed ID: 8243440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of binding equation method for prediction of unbound serum valproic acid concentration in pediatric patients with epilepsy.
    Kodama Y; Kuranari M; Kodama H; Koike Y; Yasunaga F; Fujii I; Takeyama M
    Int J Clin Pharmacol Ther; 1995 Feb; 33(2):114-8. PubMed ID: 7757310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum carnitine, beta-hydroxybutyrate and ammonia levels during valproic acid therapy.
    Toksoy HB; Tanzer FN; Atalay A
    Turk J Pediatr; 1995; 37(1):25-9. PubMed ID: 7732605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma concentrations of unbound valproate and the management of epilepsy.
    Kilpatrick CJ; Bury RW; Fullinfaw RO; Moulds RF
    Aust N Z J Med; 1987 Dec; 17(6):574-9. PubMed ID: 3128970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of significant correlation between circadian profiles of valproic acid serum levels and epileptiform electroencephalographic activity.
    Burr W; Froescher W; Hoffmann F; Stefan H
    Ther Drug Monit; 1984; 6(2):179-81. PubMed ID: 6429910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of epilepsy and valproic acid on oxidant status in children with idiopathic epilepsy.
    Yiş U; Seçkin E; Kurul SH; Kuralay F; Dirik E
    Epilepsy Res; 2009 Apr; 84(2-3):232-7. PubMed ID: 19261443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid gas chromatographic determination of valproic acid in serum.
    Arranz Peña MI
    J Chromatogr; 1981 Oct; 225(2):459-62. PubMed ID: 6795216
    [No Abstract]   [Full Text] [Related]  

  • 40. Valproate for epilepsy in renal transplant recipients receiving cyclosporine.
    Hillebrand G; Castro LA; van Scheidt W; Beukelmann D; Land W; Schmidt D
    Transplantation; 1987 Jun; 43(6):915-6. PubMed ID: 3109089
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.